ijtos 2023

International Journal of Trends on OncoScience

Review Article

AI in Cancer

Artificial Intelligence in Cancer Researches

M. Kannan[1*]

[1*]*Part Time Research Scholar, PG & Research Department of Zoology, Kandaswami Kandar's College, P.Velur- Namakkal.*

Abstract: By the early 19th century, it was commonly used to describe diseases characterized by the uncontrolled growth of abnormal cells. Cancer is one of the leading causes of death worldwide and is responsible for an estimated 9.6 million deaths in 2018 alone. Over the years, the understanding of Cancer has grown, and researchers have identified many of its causes. Factors such as lifestyle, diet, environment, and genetics have been linked to an increased risk of Cancer. As a result, public health organizations are working to reduce the number of cancer cases through awareness campaigns, early detection, and treatment. To reduce the number of cancer cases and fatalities, individuals must practice preventative measures such as healthy eating, regular exercise, and avoiding environmental hazards. It is also essential for individuals to be aware of their risk factors, receives regular screenings, and seek medical attention if any concerning symptoms arise. AI is being used to analyze huge amounts of data from past and current cancer research, enabling researchers to identify patterns in the data that could lead to new treatments and breakthroughs in curing Cancer. AI is also being used to analyze imaging data, allowing for more accurate diagnosis and early detection of Cancer. AI is further utilized to advance cancer treatment, helping develop personalized medicine tailored to individual patients' needs. This review covers Cancer Statistics, Conventional Practices for Cancer Diagnosis and Treatment, AI for Cancer Research, Cancer Data Repositories, Genomic and Molecular Data, Cloud AI Platforms, AI for Cancer Prediction, and AI for Cancer Treatment.

Keywords: Artificial intelligence; Conventional Practices; Data Repositories; Genomic and Molecular Data; Cloud AI Platforms

***Corresponding Author**

M. Kannan , Part Time Research Scholar, PG & Research Department of Zoology, Kandaswami Kandar's College, P.Velur- Namakkal.

Received On 1 December, 2022
Revised On 12 December, 2022
Accepted On 31 December, 2022
Published On 10 January, 2023

Funding This research did not receive any specific grant from any funding agencies in the public, commercial or not for profit sectors.

Citation M. Kannan , Artificial intelligence in cancer researches.(2023).Int. J. Trends in OncoSci.1(1), 19-26

1. INTRODUCTION

The word "cancer," which invaded or grew and expanded to additional body areas, began to be applied to medicine in the 1600s,[1,2]. Cancer is a complex and multidimensional condition in a standard cell cycle with many 1000 epigenetic and genetic differences, notably in how cells divide and develop. The process of mitosis is used by the cells to replicate themselves, which results in the cell's characteristic expansion. The cells eventually undergo apoptosis, a planned cell death process that ensures controlled cell proliferation. As this process becomes disorganized, the cells degenerate and lose, increasing malignant tumors that exponentially invade the mass of cells around them. The possibility exists that the cancer cell will circulate in the circulation. There are 500 or more genes linked to various types of Cancer. Among the leading causes of mortality worldwide, particularly for people under 70, is Cancer.[3] Oncology is one of the therapeutic areas advancing the most quickly globally, and an early and accurate cancer diagnosis is crucial. to improve patient survival. One that vast repositories of data linked with Cancer can be used to predict and detect early Cancer diagnosis as a result of the present research[4]attempt that are concentrated on cancer etiology and curative aspect .[3] Cancer treatments are time-consuming and costly due to increased recurrence and mortality rates of the disease. Cancer has the greatest number of therapeutically relevant outcomes due to advancements in Multidisciplinary research and clinical trials. Clinical uses of AI are in detecting and treating Cancer .[4] Using machine learning (ML) treatment will accelerate the creation of a customized treatment plan for each patient in future medical guidance. Researchers could collaborate in real-time to potentially treat millions of people and share data online. In this paper, healthcare and artificial intelligence (AI) highlight healthcare technology that alters how people view healthcare and demonstrate how medical technology is made possible by AI professionals to provide appropriate care. This knowledge is essential; therefore, medical practitioner or worker uses a certain technique because a medical techniques worker are not familiar with the impact of preventive medicine[75]

2. CANCER STATISTICS

There are 36 various types of Cancer, according to the IARC (International Agency for Research on Cancer International Agency for Research) on Cancer). According to their research, one in five persons will eventually get Cancer, and one in eight men and one in eleven females will succumb to it. Every year, eight million individuals worldwide pass away from Cancer. Breast cancer and lung cancer have the highest incidence rates in men and women, respectively, according to GLOBOCAN (Global Cancer Observatory) 2020 estimates. Lung cancer accounted for 23% of all cancer-related deaths, according to the Centers for Disease Control and Prevention (CDC), making it the form of Cancer that caused the most fatalities. Over 10 million deaths globally in 2020 were attributed to Cancer, according to a 2022 WHO assessment.[6]

2.1. Conventional Practices for Cancer Diagnosis and Treatment

A skilled clinician can diagnose Cancer non-invasively by examining prospective locations resembling the symptoms of fatal tumours[7] using a number of medical imaging.[7] The degree of accuracy of the finding is significantly influenced by the clinician's experience. As an accurate readout of these types of scans calls for years of training, radiologists frequently have different interpretations of the clone scan Due to the magnitude of the medical knowledge, this strategy is also laborious and inconsistent. The number of periods experts can devote to obtaining a disease finding is often limited, and it could be challenging to make inferences from non-standard data in several modalities. [8] The difficulty of conventional curative aspects of Cancer stems from the need to try and evaluate patient-specific treatment fusions. [9] Mechanical, physico-chemical, and biological therapy are the major approaches to remedy patients with major fatal disorders.[10] The prescribed-customized treatment plan includes either conventional modalities, such as chemotherapy, surgery, or radiation. Chemotherapies, a form of intravenous systemic therapy[8], are utilized. whenever a malignant disease is present. It is the only choice for treating metastatic illness when medication has to be administered throughout the body's entire system. [11]Chemotherapy kills cancerous cells by using medications that target cells that divide quickly.[12] The medicine utilized to reduce tumors has negative adverse consequences.

2.2. AI for Cancer Research

The promise for highly customized Oncology care has been provided using AI technology anticipated by professionals since the field's start.[13]. Keeping this commitment fulfilled as inference of numerous scientific developments, such as the development of ML (Machine Learning) and DL (Deep-L) algorithms, the diversification of databases' scope and content, including multi-omics, and decrease in the cost of massively parallelized processing capacity. The two basic ways AI imitates human intelligence are fuzzy logic and neural networks. Neural-network models, in comparison to fuzzy-logic models, produce outputs that are extremely challenging to understand and are therefore commonly known as "black box" models.[14] The symbolic AI (SAI) paradigm is directed by human-domain knowledge in contrast to the data-driven AI (DAI) paradigm, which is guided by data. SAI connects signs in a relationship that are readable by humans comparable to "if-then" phrases to reach conclusions and is most frequently used in deterministic settings. AI Computer methods are improved by explicitly incorporating human knowledge and norms to assist in circumstances where basic guidelines are adequate to solve the problem. [15] This enables using computer machines to cause informed decisions; in other words, DAI develops mathematics equations that utilize past data as experience. Due to the accessibility of open-healthcare sources [17]data, researchers have created tools to aid in the diagnosis and prognosis of Cancer. DL and ML models use distributed datasets to provide reliable rapid, and well-organized answers to difficulties in cancer medical treatment. Advanced federated learning models can be used to analyze dispersed data. Some of the newly developed clinically helpful approaches include whole-blood, multi-cancer diagnosis utilizing virtual biopsies and deep sequencing, NLP (National Language Processing) to using medical records to estimate health trajectories and.[42] For cancer risk assessment, and illness diagnosis, improved systems to support clinical decisionsinclude clinical genomics and prognosis staging, therapy, and oversight surveillance. Oncology heavily relies on evidence-based, medicine-. powered cancer study is agreeable persons without considerable computer expertise when supported by solid An essential resources and services.[14] The use of algorithm-based AI for interpreting radiological images, EHRs,(Electronic Health Records) using data mining to provide a highly accurate cancer treatment is projected to change how clinical practices and digital healthcare are delivered. According to marketing-cancer-research companies, the cost reductions from clever AI applications in American healthcare are expected for 2021 to be $52 billion. [18] If appropriate, there are data for building the ML and DL reference AI that could play a bigger role in cancer research. Successful.

2.3. Cancer Data Repositories

The term "digital health relates to the usage of electronic transformation in healthcare [19]sector and includes software, data, technology, and services. According to Deloitte Insights, data interoperability and AI offer user- and hindrance-focused healthcare. Data accessibility is crucial for data-driven AI research, and the inability to get sufficient data can frustrate many researchers[20]. Cancer researchers are always creating new clinical trials to learn how to improve cancer care, therapy, and prevention. Several concerns offer online directories of active clinical trialsto help participants find research studies that might be appropriate for them[21] and to find a Cancer clinical, such as databases Ancora.ai,[22] Jeremy Carter Program for Clinical Trials Search and Support [23,] Network for Advocacy in Bladder Cancer[24], BreastCancerTrials.org[25], Center Watch ClinicalTrials.gov Center for Information and Studies on Clinical Research Participation (CISCRP).[26-28]; Clinical Trial Navigator Service by EmergingMed[29], Lazarex Fund for Cancer[30], Association for Melanoma Research[31], Project for Metastatic Breast Cancer[32], Metastatic Prostate Cancer Project on [33], National Brain Tumor Society Clinical Trial Locator for the[34],American Cancer Society (NCI) Therapeutic Trials[35], Clinical Trial [36,37], Locator for Pancreatic Cancer Action Network SPOHNC Clinical[38-40]. The National Cancer Institute (NCI) , Cancer Imaging Program (CIP) supports and advances fundamental, translational, and clinical imaging. [41-43] Studies that are tied to both Cancer and the incorporation of the use of these imaging developments to deal with oncology is the prevention of cancer and cancer treatment,[44-45] The website Cancer centre.ai includes information such as screen captures from the imaging platform showing an MRI (Magnetic Resonance Imaging) of the prostate (T2-weighted images in axial plane). It offers pre-screened photos and attributes that expert radiologists have found. The Cancer Imaging Archive (TCIA): TCIA offers the general public access to a substantial collection of cancer-related medical images *for downloading*.[46] (Magnetic Resonance *Imaging)* (Computed *Tomography) offered* picture types, including digital histopathology, MRI, and CT. Radiomic features that can evaluate tumor vigor form have been used to improve oncological findings, therapeutic response, and prognosis.[47] In clinical radiographic imaging, computer-aided detection (CADe) or computer-aided diagnosis (CADx) is the system-based architecture that helps professionals make decisions fast. The detection and segmentation of Cancer can be aided by MRI-derived Digital Imaging and Communications in Medicine (DICOM) images with improved *accuracy* in making predictions. In roughly 23% of the literature, a Computed Tomography (CT) scan was used for conditioning the mode. In addition, pathological and endoscopic have all been extensively used in the study. The poor contrast of CT-scan images makes it hard to identify a thing from imaging using *a* mammogram background, making categorizing more difficult. DL-based detection techniques can reduce experimental omission mistakes and serve as a primary protection against them. [48] Characterization, in a broad sense, encompasses tumor finding, staging the phase and segmentation of anomalies, and detecting determinant nodules. Analytically, these problems are addressed by [49] individual qualitative attributes. Still, CADx systems analyze quantitative tumor data systematically, enabling more reiterable explanations to capture the heterogeneity within a tumor when a strong tumor descriptions are given. Notwithstanding, traditional biological statistics approaches have successfully addressed many of the issues with lung cancer screening, these techniques could be replaced by identifying biomarkers that more accurately differentiate malignant and benign nodules.

2.4. Genomic and Molecular Data

The Cancer Genome Atlas (TCGA) is a widely used online resource for cancer research that generates a variety of data and tools from over 20,000 cancer samples from 33 different cancer types. ICGC (International Cancer Genome Consortium): It identifies the genetic defects in fifty of the many major Cancer types.[50] Every information from the 25,000 cancer models studied is made available to researchers studying Cancer all across the world for free. Visualization and analysis bring in, BioPortal datasets as MultiAssay Experiment Bioconductor components are all possible with BioPortal Data. In Cancer drug sensitivity genetics, more than `100 human tumor cells are characterized by it and lead compounds are tested on them. Additionally, it provides details on genetic sensitivity indicators and treatment response. Precision medicine may be compromised by the multiple barriers keeping customized treatments out of reach.[51] The key challenge is collecting, analyzing, and applying gene-related information about patients. Researchers and service givers increasingly use AI to extract practical insights from genetic information. Making precision-medicine treatments a reality is the first step in changing genomic information incomprehensible source to a valuable medical asset that will heavily rely on AI. AI is capable of understanding the many pathologies of Cancer with related symptoms. Nonetheless, the statistics misrepresentation can lead to conclusions that are not in the best interests of every patient[52.] ML/DL algorithms can overcome the limitations of traditional computational methods by finding patterns across all the transcriptome. The character's selection method is key in determining how well AI performs even when processing complex variations.[53] Processing is more difficult due to the enormous Indicator of data, especially omics high-throughput. After character selection, the most crucial variables may be discovered, which decreases dimensionality, shortens the practice period, increases the model's ability to generalize, and avoids overfitting. When AI models employ a trustworthy feature-extraction technique, their performance will undoubtedly improve. AI can be used to fulfill a variety, such as calling and annotating variants impact prediction for variant and phenotype-to-mapping of genotypes. It may sometimes be unclear how particular classes of consequences and AI diagnostic tasks are related. Computer visualizes the human genome and can be used to identify physiological regulatory components in the human totality of DNA, for example, by spotting recurring motifs in DNA arrangement like how CNN picks upper variations in photographs.[54] Deep learning (DL) has resolved many of these problems, which use complex network topologies to extract understandable features from extremely complex datasets. CNNs subdivide the input-DNA arrangement into samples used for the information from the sub-samples with masks, multiplying each feature value by a particular set of weights. Patterns in the findings are related to the original sequence. A classifier can be trained using these feature maps to.[55]

2.5. *Pathological Images*

Pathology departments produce digital slides using the Whole Slide Imaging Repository- a repository of scanned images of conventional glass slides. Digital Slide Library for Cancer: It houses pathological picture collections. By testing cell, tissue, and physiological liquid samples, the science of pathology primarily focuses on diagnosing disorders. For example, the prostate, lung, and breast are only a few of the many different tissue types that fall under the broad umbrella of pathology.[56]Hematoxylin and Eosin (H&E) slide images are frequently used to diagnose cancer or benign conditions on the tissue that can serve as the foundation for a range of specialized interpretations or scoring techniques, pathology AI systems must be developed. Applying AI- and ML using computational tools is becoming increasingly crucial in digital pathology. It can utilize DNN models to produce accurate, high-resolution tumor images and new biomarkers. [57] The biology traces can distinguish the human body's cells and tissues. They are known as biomarkers. The foundation for digitalizing medical pathology, a crucial advancement for improved cancer diagnostics, is the translation of high-resolution photos of histopathology slides by slide scanners.[58] Digital whole slide images (WSIs), which are being analyzed utilizing ML systems for DL analytical processing, can enable an understanding of biological complexity in cellular architecture. However, owing to the variances in pathology middle of various patient kinds, a fully automated AI does not recommend.

2.6. *Using Cloud AI Platforms*

Thanks to the emergence of zero-code AI platforms, health professionals can now use AI without knowledge through leveraging APIs. The development of AI for Cancer depends on the trifecta algorithms for computation use of databases and the power of computing techniques because of the inherent data richness field. Each of these AI tenets must be stretched beyond its current bounds to attain the level of accuracy that oncology requires aspires. Medical specialists from all around the world are trading knowledge of the finding of treatment of illnesses, the effectiveness of medications, and effective disease control techniques.[59] Additionally, such data may be automatically archived in the cloud using AI processing capacity to find insights. Distant servers with internet access are the essence of cloud computing. Microsoft's huge investment in cloud computing makes sense for a field that needs a lot of computational power to tackle complex problems[60]. Jasmin Fisher, a bioscientist at Microsoft Cambridge, U.K., created the Bio Model Analyzer (BMA). This cloud-based programmer enables biologists to mimic how cells interact and converse with each other and uncover the links they create. A cloud-based system called Literome can organize genetic studies and may be helpful in the early detection of Cancer. Due to the abundance of data, oncologists would need help completing their duties independently. As a way to create Literome, the usage of which NLP, Hoifung Poon, a researcher at Microsoft's Redmond, Washington lab, employed ML to construct advanced models for finding alternative descriptions of the same knowledge. The cloud-based platform, the link that joins scientists to numerous tumor data sets and offers the tools and resources for analysis and computing to analyze that data fast, is supported by Big Query, a highly scalable, multi-cloud data warehouse from Google Cloud. Now, data on the Institute of Science Biology-Cancer Genomic Cloud (ISB-CGC) platform may be directly analyzed by medical researchers without the need to Obtain it utilizing Google Cloud services like Notebooks and Big Query application programming interfaces (APIs). With Google Cloud as the foundation of their cloud-based infrastructure and data approach, ISB-CGC has successfully given the research community for Cancer secure, real-time usage of information essential before diagnosis.

2.7. *AI for Cancer Prediction*

AI-powered predictive models are a vital part of the curative aspect[61]. By recognizing the risk variables, predictive models can determine a person's likelihood of developing specific cancer. AI can identify people catching the disease before it spreads. It makes it possible for medical experts who pose a serious threat to monitor these sufferers and take prompt action closely. According to the University of Hawaii researchers, DL can distinguish in the middle of mammograms taken from women who would go on to breast cancer and those who would not. [62] To forecast cancer risk from mammography pictures, MIT (Massachusetts Institute of Technology) researchers have created a robust learning (DL) model. They used information from numerous hospitals on various continents to validate the model. The algorithm is accurate.

2.8. *AI for Cancer Treatment*

A tumor's rate of growth, whether it has spread, and whether it is like to come back after treatment is all elements that must be considered while treating Cancer, even if the usage of surgery, chemotherapy, and radiation therapy which is always a benchmark of excellence for the treatment of cancer.[63]For better results with cancer therapy and diagnosis, an individualized treatment plan is becoming more and more crucial. The timing of restaging and monitoring exams, the dosages of radiation and medications for systemic neoplasm, and the selection and order of evaluation and treatment procedures are some ground-breaking ways this technology could prolong life and enable more cures. Because of the variety of tumor types, sites, and sizes, automating the contouring of cancer targets using DL is still quite challenging. The improvement of therapeutic options over the last fifty years are of greatly increased. The ordinary life span for many people with Cancer can be attempted to increase with the aid of AI. Early finding imaging technology, highly individualized targeted radiation treatment chemotherapy based on knowledge of immunotherapies, and the totality of human DNA have all made this possible. [64] High cancer lesions at risk- can be accurately predicted using image-based ML techniques. Volumetric imaging organs at risk (OAR) segmentation, target volume segmentation, treatment planning, treatment administration, and follow-up are all parts of the radiotherapy workflow. When called of the radiation process, quality assurance (QA) is the last step of verifying the acceptance of the treatment by the medical community and verifies the efficacy of the entire workflow. The contours of the radioactive field are one of the most important forms of radiation. Medical experts can use big data and AI to analyze a span of patient and cancer cell data to create individualized treatments. Less severe side effects will result from this type of therapy. Healthy cells will suffer less damage, but cancer cells will be more significantly affected. Cedars Sinai Cancer created molecular twins of cancer patients, an AI and specific medicine business based in Chicago used the curative aspects of Cancer AI [65], which resembles those people like monozygotic twins that help choose the most effective course of cancer treatment for a certain patient since they have information such as DNA, RNA, and proteins. Supported by the understanding of causality rather than just correlations and weightings of medical data variables. Another important area where artificial intelligence has made a considerable contribution is in the repurposing and creative drug designing. AI can anticipate how different medications will impact cancerous cells. [66] The development of novel Cancer against drugs and time of administration is aided by this information. Medicine creation is a costly and time-consuming procedure, but AI can increase productivity by using neural networks. Reinforcement practice, roughly the statistical relationship between prospective outcomes and deep learning (DL), together produce a ground-breaking method for discovering novel therapeutic molecules. AI can change every aspect of the pharmaceutical lifecycle, from regulatory procedures to pharmacovigilance. Several computer tools have been proposed for identifying cancer-related drugs based on various AI approaches. STITCH, Alpha Fold, Deep Neural Net QSAR, Deep Chem, DeepTox, gene2drug, etc.

2.9. Challenges

Even though AI has many benefits, it is limited by several issues that hinder it from performing to its full potential inthe field of cancer research.[67] The most recent innovation wave has many benefits; challenges must be overcome to alter cancer processes at various sizes significantly. Many obstacles to appropriately utilizing AI include rules, payments, expertise, practical issues, and rigid healthcare systems. Correcting AI models for classifiers and predictors needs labeled data. Insufficient data can be present in AI datasets requiring curation. Many specialists in the area should be included in the data process to analyze the information labels appropriately. The lack of multiple subject experts in the data-annotation process is a major obstacle to creat new cancer treatments for standardized information on the disease.[68] Many research has demonstrated excellent AI in neoplasm outcomes. However, a computationally effective quality- strategy is required to eliminate data-cleaning processes and achieve high accuracy in cancer prediction. Research has to be refocused on improving the model. Most studies have proposed [69]a models for predictors and classifiers only in one region. For the models to be several generalizable, many sites must be used to validate them. As was already established, it need help to achieve repeatability of results from AI models when used in various foreign populations. However, even inside of context wherein they are used, advanced decision-and AI programmers are susceptible data. Deep architectural problems can sometimes be resolved by utilizing efficient and effective maximize, intelligent strategies, and activate .[70] Since the assembling of numerous non-linear transformations, many challenges remain for in-depth network training. Issues need to be fixed. Although methods to detect in-model training efficacy still has to be increased. DL methods have received about 90 percent of the research's validation compared to other methods.[67] Yet, the DL-based methods are very challenging. The classifier for CNN was utilized in around 41 percent of the studies, and at a significant computational cost. The absence of expertise among therapists and health practitioners in computer programs and technology may further hinder the implementation of Artificial Intelligence in several developing countries. Clinical detection programs are used today to be as feeble AI. In other words, they are skilled in only one activity and need more general intelligence in addition to the adaptability of multiple clinical jobs. Yet, utilizing transfer-learning strategies, an AI algorithm that has been thoroughly trained changed to perform closely associated tasks.[71]

3. CONFLICT OF INTEREST

Conflict of interest declared none.

4. REFERENCES

1. Shaikh K, Krishnan S, Thanki RM. Artificial intelligence in breast cancer early detection and diagnosis. New York: Springer; 2021.
2. Zhou J, Tang Z, Gao S, Li C, Feng Y, Zhou X. Tumor-associated macrophages: recent insights and therapies. Front Oncol. 2020 Feb 25;10:188. doi 10.3389/font.2020.00188, PMID 32161718.
3. Banfi A, Muraglia A, Dozin B, Mastrogiacomo M, Cancedda R, Quarto R. Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: implications for their use in cell therapy. Exp Hematol. 2000 Jun 1;28(6):707-15. doi: 10.1016/s0301-472x(00)00160-0, PMID 10880757.
4. Perri F, Di Lorenzo GD, Scarpati GD, Buonerba C. Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options. World J Clin Oncol. 2011 Mar 3;2(3):150-7. doi: 10.5306/wjco.v2.i3.150, PMID 21611089.
5. Conroy MB, Delichatsios HK, Hafler JP, Rigotti NA. Impact of a preventive medicine and nutrition curriculum for medical students. Am J Prev Med. 2004 Jul 1;27(1):77-80. doi 10.1016/j.amepre.2004.03.009, PMID 15212779.
6. Jani C, Marshall DC, Singh H, Goodall R, Shalhoub J, Al Omari O et al. Lung cancer mortality in Europe and the USA between 2000 and 2017: an observational analysis. ERJ Open Res. 2021 Oct 1;7(4). doi: 10.1183/23120541.00311-2021, PMID 34988220.
7. Roder D. Epidemiology of Cancer in Indigenous Australians: implications for service delivery. Cancer Forum. 2007 Jul (Vol. 31, No. 2, pp. 85-90).
8. Jedariforoughi A. A qualitative survey about a patient's experiences and expectations of meeting healthcare professionals during multiple acute hospitalizations and follow-up periods. Doctmedico [journal]. 2022 Feb;2(1):180-93.
9. Verhoef MJ, Rose MS, White M, Balneaves LG. Is it declining conventional cancer treatment and using

complementary and alternative medicine: a problem or a challenge? Curr Oncol. 2008 Aug;15;Suppl 2:s101-6. doi 10.3747/co.v15i0.281, PMID 18769571.
10. Donkadokula NY, Kola AK, Naz I, Saroj D. A review on advanced physico-chemical and biological textile dye wastewater treatment techniques. Rev Environ Sci Biotechnol. 2020 Sep;19(3):543-60. doi: 10.1007/s11157-020-09543-z.Donkadokula NY. Donkadokula NY, Kola AK, Naz I, Saroj D. A review on advanced physico-chemical and biological textile dye wastewater treatment techniques. Rev Environ Sci Biotechnol. 2020 Sep;19(3):543-60. doi: 10.1007/s11157-020-09543-z.
11. Kirkham MA. Accessing and assessing fibromyalgia through pain drawings. United Kingdom: Bangor University; 2010.
12. Nagahashi M, Shimada Y, Ichikawa H, Kameyama H, Takabe K, Okuda S et al. Next-generation sequencing-based gene panel tests for the management of solid tumors. Cancer Sci. 2019 Jan;110(1):6-15. doi 10.1111/cas.13837, PMID 30338623.
13. Meredith LS, Bouskill K, Chang J, Larkin J, Motala A, Hempel S. Predictors of burnout among US healthcare providers: a systematic review. BMJ Open. 2022 Aug 1;12(8):e054243. doi: 10.1136/bmjopen-2021-054243, PMID 36008065.
14. Ferreyra E, Hagras H, Kern M, Owusu G. Depicting decision-making: A Type-2 fuzzy logic based explainable artificial intelligence system for goal-driven simulation in the workforce allocation domain. IEEE Int Conf Fuzzy Syst (FUZZ-IEEE). 2019 Jun 23:(1-6). doi 10.1109/FUZZ-IEEE.2019.8858933.
15. Johnson M, Albizri A, Harfouche A, Fosso-Wamba S. Integrating human knowledge into artificial intelligence for complex and ill-structured problems: informed artificial intelligence. Int J Inf Manag. 2022 Jun 1;64:102479. doi: 10.1016/j.ijinfomgt.2022.102479.
16. Sebastian AM, Peter D. Artificial intelligence in cancer research: trends, challenges, and future directions. Life (Basel). 2022 Nov 28;12(12):1991. doi: 10.3390/life12121991, PMID 36556356.
17. Ashri R. The AI-powered workplace: how artificial intelligence, data, and messaging platforms define the future of work. Apress; 2019 Dec 9.
18. Elayan H, Aloqaily M, Guizani M. Digital twin for intelligent context-aware IoT healthcare systems. IEEE Internet Things J. 2021 Jan 12;8(23):16749-57. doi 10.1109/JIOT.2021.3051158.
19. Parati G, Pellegrini D, Torlasco C. How digital health can be applied for preventing and managing hypertension. Curr Hypertens Rep. 2019 May;21(5):40. doi: 10.1007/s11906-019-0940-0, PMID 31011866.
20. Dessie T, OkeyoMwai A. The story of cattle in Africa: why diversity matters. ILRI (aka ILCA and ILRAD); 2019 Dec 31.
21. Till JE, Phillips RA, Jadad AR. Finding Canadian cancer clinical trials online: an exploratory evaluation of online resources. CMAJ. 2003 Apr 29;168(9):1127-9. PMID 12719315.
22. Bruschetta S, Bellia V, Barone R. Manifesto per una psicoterapia di comunità a sostegno della partecipazione sociale: la psicoterapia individuale e quella di gruppo rispondono ancora ai bisogni di cura della società?. Rivista Plexus. 2015 Oct 29(14-15).
23. Carter JG, Mohler G, Raje R, Chowdhury N, Pandey S. The Indianapolis harm spot policing experiment. J Crim Justice. 2021 May 1;74:101814. doi 10.1016/j.jcrimjus.2021.101814.
24. Dole VP, Nyswander M. A Medical Treatment for Diacetylmorphine (Heroin) Addiction. A Clinical Trial with Methadone Hydrochloride. Jama. 1965 Aug 23;193(8):646-50. doi 10.1001/jama.1965.03090080008002, PMID 14321530.
25. Cohen EJ, Belkora JK, McCreary E, Colen S, Maple T, Bechtold T et al. BreastCancerTrials. org: early Evaluation of a Nationwide Clinical Trial Matching Service. Cancer Res. 2010 Dec 15;70(24):5-07: Abstract P5-07-01:
26. Nelson AM. Generational value differences impacting the perceptions of and willingness for clinical trial participation ([doctoral dissertation]. Eastern Michigan University).
27. Bamford J. The NSA is building the country's biggest spy center (watch what you say). Wired; 2012 Mar 15, Mar. 15.
28. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database—update and key issues. N Engl J Med. 2011 Mar 3;364(9):852-60. doi: 10.1056/NEJMsa1012065, PMID 21366476.
29. Moffitt K, Brogan F, Brown C, Kasper M, Rosenblatt J, Smallridge R et al. Statewide cancer clinical trial navigation service. J Oncol Pract. 2010 May;6(3):127-32. doi 10.1200/JOP.200006, PMID 20808555.
30. Mueller KL, Theoret MR, Lemery SJ, Amiri-Kordestani L, Ariyan CE, Atkins MB, et al. Neoadjuvant Therapy for Melanoma: a U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop. Clin Cancer Res. 2021 Jan 15;27(2):394-401. doi 10.1158/1078-0432.CCR-20-3285, PMID 33188142.
31. Wagle N, Painter C, Krevalin M, Oh C, Anderka K, Larkin K et al. The Metastatic Breast Cancer Project: A national direct-to-patient initiative to accelerate genomics research. J Clin Oncol. 2016 Jun 20;34(18).
32. Wang S, Ji Y, Chen Y, Du P, Cao Y, Yang X et al. The Values of Systemic Immune-Inflammation Index and Neutrophil-Lymphocyte Ratio in the Localized Prostate Cancer and Benign Prostate Hyperplasia: a Retrospective Clinical Study. Front Oncol. 2021;11:812319. doi: 10.3389/fonc.2021.812319. PMID 35047413.
33. Anitha C, Gnanatheepa KC, Hubert G, Yadav R, Naik SB, Singh B. Ai-based herbal treatment for the cancer cell. J Pharm Neg Results. 2022 Dec 31:7623-36.
34. Rocker C, Cappelletti L, Marshall C, Meunier CC, Brooks DW, Sherer T et al. Use of an online portal to facilitate clinical trial recruitment: a preliminary analysis of Fox Trial Finder. J Parkinsons Dis. 2015 Jan 1;5(1):55-66. doi: 10.3233/JPD-140522, PMID 25624422.
35. Pancreatic Cancer Action Network. SPOHNC Clinicalator for PancrSebastian AM, Peter D. Artificial intelligence in cancer research: trends, challenges, and future directions. Life. 2022 Nov 28;12(12):1991.eatic Cancer Action Network SPOHNC Clinicalocker C. Rocker C, Cappelletti L, Marshall C, Meunier CC, Brooks DW, Sherer T, et al. Use of an online portal to facilitate clinical trial recruitment: a preliminary analysis of Fox Trial Finder. J Parkinsons Dis. 2015 Jan 1;5(1):55-66. doi: 10.3233/JPD-140522, PMID 25624422.

36. Bleyer WA, Tejeda H, Murphy SB, Robison LL, Ross JA, Pollock BH et al. National cancer clinical trials: children have equal access; adolescents do not. J Adolesc Health. 1997 Dec 1;21(6):366-73. doi: 10.1016/S1054-139X(97)00110-9, PMID 9401854.
37. Sebastian AM, Peter D. Artificial intelligence in cancer research: trends, challenges, and future directions. Life (Basel). 2022 Nov 28;12(12):1991. doi: 10.3390/life12121991, PMID 36556356.
38. American Society of Clinical Oncology. Targeted agent and profiling utilization registry (TAPUR) study.
39. Pasqualucci L, Bereshchenko O, Niu H, Klein U, Basso K, Guglielmino R et al. Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6. Leuk Lymphoma. 2003 Nov 1;44;Suppl 3:S5-12. doi: 10.1080/10428190310001621588, PMID 15202519.
40. Dumanovsky T, Augustin R, Rogers M, Lettang K, Meier DE, Morrison RS. The Growth of Palliative Care in U.S. Hospitals: a Status Report. J Palliat Med. 2016 Jan 1;19(1):8-15. doi: 10.1089/jpm.2015.0351, PMID 26417923.
41. Moja LP, Moschetti I, Nurbhai M, Compagnoni A, Liberati A, Grimshaw JM, et al. Compliance of clinical trial registries with the World Health Organization minimum data set: a survey. Trials. 2009;10:56. doi 10.1186/1745-6215-10-56. PMID 19624821.
42. Murphy TL, Murphy KM. Dendritic cells in cancer immunology. Cell Mol Immunol. 2022 Jan;19(1):3-13. doi: 10.1038/s41423-021-00741-5, PMID 34480145.
43. Burgess R. Understanding nanomedicine: an introductory textbook. CRC Press; 2012 Jun 18.
44. Liu Q, Li J, Liu F, Yang W, Ding J, Chen W, et al. A radiomics nomogram for the prediction of overall survival in patients with hepatocellular carcinoma after hepatectomy. Cancer Imaging. 2020 Dec;20(1):82. doi: 10.1186/s40644-020-00360-9, PMID 33198809.
45. Strobel K, Heinrich S, Bhure U, Soyka J, Veit-Haibach P, Pestalozzi BC et al. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing pancreatic cancer resectability. J Nucl Med. 2008 Sep 1;49(9):1408-13. doi: 10.2967/jumped.108.051466, PMID 18703604.
46. Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, et al. Noninvasive non-small cell lung cancer staging: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep 1;132(3);Suppl:178S-201S. doi: 10.1378/chest.07-1360, PMID 17873168.
47. Nevedomskaya E, Haendler B. From omics to multi-omics approaches for in-depth analysis of the molecular mechanisms of prostate cancer. Int J Mol Sci. 2022 Jun 3;23(11):6281. doi: 10.3390/ijms23116281, PMID 35682963.
48. Sebastian AM, Peter D. Artificial intelligence in cancer research: trends, challenges, and future directions. Life (Basel). 2022 Nov 28;12(12):1991. doi: 10.3390/life12121991, PMID 36556356.
49. Schleindl HM. Social inequality in Australia: measurement and theory. Australia: Australian National University; 1975.
50. Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Mol Divers. 2021 Aug;25(3):1315-60. doi: 10.1007/s11030-021-10217-3, PMID 33844136.
51. Garrett ES, Eaton WW, Zeger S. Methods for evaluating the performance of diagnostic tests in the absence of a gold standard: a latent class model approach. Stat Med. 2002 May 15;21(9):1289-307. doi 10.1002/sim.1105, PMID 12111879.
52. Von Wintzingerode F, Göbel UB, Stackebrandt E. Determination of microbial diversity in environmental samples: pitfalls of PCR-based rRNA analysis. FEMS Microbiol Rev. 1997 Nov 1;21(3):213-29. doi 10.1111/j.1574-6976.1997.tb00351.x, PMID 9451814.
53. Close JL, Kosty M, Gilbert J. 4 competencies required in the curriculum. ESMO ASCO Recomm Glob Curriculum Med Oncol Ed. 2016;144:9:2011.
54. Niazi MKK, Parwani AV, Gurcan MN. Digital pathology and artificial intelligence. Lancet Oncol. 2019 May 1;20(5):e253-61. doi: 10.1016/S1470-2045(19)30154-8, PMID 31044723.
55. Kumar S, Raut RD, Narkhede BE. A proposed collaborative framework by using artificial intelligence-internet of things (AI-IoT) in the COVID-19 pandemic situation for healthcare workers. Int J Healthc Manag. 2020 Oct 1;13(4):337-45. doi 10.1080/20479700.2020.1810453.
56. Oono IP, Honey EJ, McConachie H. Parent-mediated early intervention for young children with autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2013;(4): CD009774. doi: 10.1002/14651858.CD009774.pub2. PMID 23633377.
57. Clemons EK, Weber BW. London's Big Bang: a Case Study of Information Technology, Competitive Impact, and Organizational Change 1. J Manag Inf Syst. 1990 Mar 1;6(4):41-60. doi 10.1080/07421222.1990.11517871.
58. Zhang Z, Genc Y, Wang D, Ahsen ME, Fan X. Effect of ai explanations on human perceptions of patient-facing ai-powered healthcare systems. J Med Syst. 2021 Jun;45(6):64. doi: 10.1007/s10916-021-01743-6, PMID 33948743.
59. Giuliani E, Melegari G, Carrieri F, Barbieri A. Overview of the main challenges in shared decision making in a multicultural and diverse society in the intensive and critical care setting. J Eval Clin Pract. 2020 Apr;26(2):520-3. doi: 10.1111/jep.13300, PMID 31661726.
60. Huo J, Du XL, Lairson DR, Chan W, Jiang J, Buchholz TA et al. Utilization of surgery, chemotherapy, radiation therapy, and hospice at the end of life for patients diagnosed with metastatic melanoma. Am J Clin Oncol. 2015 Jun;38(3):235-41. doi: 10.1097/COC.0b013e31829378f9, PMID 23648436.
61. Lee DW, Foster DA. The association between hospital outcomes and diagnostic imaging: early findings. J Am Coll Radiol. 2009 Nov 1;6(11):780-5. doi: 10.1016/j.jacr.2009.08.007, PMID 19878885.
62. Ngiam KY, Khor IW. W. Big data and machine learning algorithms for health-care delivery. Lancet Oncol. 2019 May 1;20(5):e262-73. doi: 10.1016/S1470-2045(19)30149-4, PMID 31044724.
63. Ozsoy MG, Özyer T, Polat F, Alhajj R. Realizing drug repositioning by adapting a recommendation system to handle the process. BMC Bioinformatics. 2018 Dec;19(1):136. doi: 10.1186/s12859-018-2142-1, PMID 29649971.
64. Sebastian AM, Peter D. Artificial intelligence in cancer research: trends, challenges, and future directions. Life

(Basel). 2022 Nov 28;12(12):1991. doi: 10.3390/life12121991, PMID 36556356.
65. Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW. An updated catalog of prostate cancer predictive tools. Cancer. 2008 Dec 1;113(11):3075-99. doi: 10.1002/cncr.23908, PMID 18823041.
66. Lameire N, Joffe P, Wiedemann M. Healthcare systems-an international review: an overview. Nephrol Dial Transplant. 1999 Dec 1;14; Suppl 6(suppl_6):3-9. doi: 10.1093/ndt/14.suppl_6.3, PMID 10528706.
67. Geller AC, Swetter SM, Brooks K, Demierre MF, Yaroch AL. Screening, early detection, and trends for melanoma: current status (2000-2006) and future directions. J Am Acad Dermatol. 2007 Oct 1;57(4):555-72; quiz 573. doi: 10.1016/j.jaad.2007.06.032, PMID 17870429.
68. Moja LP, Moschetti I, Nurbhai M, Compagnoni A, Liberati A, Grimshaw . M., Chan AW, K. Dickersin, K. Kleza-Jeric, D. Moher, and I. Sim. An assessment of the World Health Organization's minimal data set compliance for clinical trial registries. Trials. 2009 Dec;10(1):1-2.) fmoja.